The contributions of cyclooxygenase-2 to tumor angiogenesis

Cancer and Metastasis Reviews

Volumn 19, Issue 1-2, 2000, Pages 19-27

  Gately, S ^a  

^a Searle Building 3 431 ^*  (United States)

Author keywords

Angiogenesis; Apoptosis; Cyclooxygenase 2; Prostaglandins; Vascular endothelial growth factor

Indexed keywords

CYCLOOXYGENASE 2; CYTOKINE; GROWTH FACTOR; PROSTAGLANDIN; PROTEIN BCL 2; THROMBOXANE A2; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; CELL MIGRATION; EMBRYO DEVELOPMENT; ENZYME LOCALIZATION; HUMAN; HUMAN CELL; HYPOXIA; IMMEDIATE EARLY GENE; MICROVASCULATURE; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; STROMA CELL; TARGET CELL; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; HUMANS; ISOENZYMES; LYMPHOKINES; MEMBRANE PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034530889     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026575610124     Document Type: Review

References (144)

1. Tumor angiogenesis: Therapeutic implications
2. Angiogenesis
3. Id1 and Id3 are required for neurogenesis, angiogenesis, vascularization of tumour xenografts
4. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
5. Angiogenesis and tumor metastasis
6. Tumor angiogenesis: Past, present and the near future
7. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma
8. Angiogenic factors
9. Angiogenesis and cancer control: From concept to therapeutic trial
10. Proteolytic balance and capillary morphogenesis
11. Angiogenesis: A paradigm for balanced extracellular proteolysis during cell migration and morphogenesis
12. First steps of tumor-related angiogenesis
13. Current concepts of tumor-induced angiogenesis
14. Angiogenesis and the fibrinolytic system
15. Tumor-associated angiogenesis: Mechanisms, clinical implications and therapeutic strategies
16. Angiogenesis: An update
17. Capillary growth: A two-cell system
18. Control of angiogenesis by the pericyte: Molecular mechanisms and significance
19. Pericyte involvement in capillary sprouting during angiogenesis in situ
20. Vasculogenesis
21. Vascular development: Cellular and molecular regulation
22. Vasculogenesis and angiogenesis: Two distinct morphogenetic mechanisms establish embryonic vascular pattern
23. Vasculogenesis and angiogenesis in embryonic-stem-cell-derived embryoid bodies
24. Relationship between vasculogenesis, angiogenesis and haemopoiesis during avian ontogeny
25. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors
26. Circulating endothelial precursors: Mystery, reality, and promise
27. Isolation of putative progenitor endothelial cells for angiogenesis
28. Angiogenesis, angiogenesis inhibition: An overview
29. New perspectives in clinical oncology from angiogenesis research
30. Angiogenesis in cancer, vascular, rheumatoid and other disease
31. The role of angiogenesis in tumor growth
32. Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo
33. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
34. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin
35. Combined effects of angiostatin and ionizing radiation in antitumour therapy
36. Vascular occlusion and tumour cell death
37. Antiangiogenic and antitumor activities of cyclooxygenase- 2 inhibitors
38. COX-2 inhibitors. A new class of antiangiogenic agents
39. Cyclooxygenases 1 and 2
40. Molecular pathology of cyclooxygenase-2 in neoplasia
41. Cyclooxygenase in biology and disease
42. Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation
43. Rapid and transient induction of cyclo-oxygenase 2 by epidermal growth factor in human amnion-derived WISH cells
44. Transforming growth factor-betal enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA
45. Differential regulation of cyclooxygenases 1 and 2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts
46. Tumor necrosis factor-alpha promotes sustained cyclooxygenase-2 expression: Attenuation by dexamethasone and NSAIDs
47. Tumor angiogenesis inhibition by prostaglandin synthetase inhibitors
48. Suppressive effects of indomethacin on thermally induced neovascularization of rabbit corneas
49. Characterization and quantification of copper sulfate-induced vascularization of the rabbit cornea
50. Role of prostaglandin El and copper in angiogenesis
51. Evidence that indomethacin inhibits lymphocyte-induced angiogenesis
52. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing
53. Interleukin 12 and indomethacin exert a synergistic, angiogenesis-dependent antitumor activity in mice
54. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
55. A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells
56. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition
57. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
58. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-([4]-hydroxybutyl)nitrosamine
59. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
60. Host cyclooxygenase-2 modulates carcinoma growth
61. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo
62. Inhibition of cyclooxygenase-2 gene expression by p53
63. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity
64. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
65. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis
66. Cyclooxygenase-2 activity is necessary for the angiogenic properties of oncostatin
67. Expression of cyclooxygenase 1 and 2 by human gastric endothelial cells
68. The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the rat
69. Hypoxia induces high-mobility-group protein I(Y), transcription of the cyclooxygenase-2 gene in human vascular endothelium
70. Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells
71. Stimulation of prostaglandin synthesis by human endothelial cells exposed to hypoxia
72. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
73. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer
74. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter
75. Induction of interleukin 6 (IL-6) by hypoxia in vascular cells. Central role of the binding site for nuclear factor-IL-6
76. Hypoxic induction of interleukin-8 gene expression in human endothelial cells
77. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells
78. Cox-2, iNOS and p53 as play-makers of tumor angiogenesis
79. Molecular pathology of cyclooxygenase-2 in neoplasia
80. Tumor induction of VEGF promoter activity in stromal cells
81. Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants
82. Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells
83. Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP
84. Reciprocal paracrine interactions between tumour cells and endothelial cells: The 'angiogenesis progression' hypothesis
85. Differential stimulation by PGE(2) and calcemic hormones of IL-6 in stromal/osteoblastic cells
86. The regulation of aromatase activity in breast fibroblasts: The role of interleukin-6 and prostaglandin E2
87. Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: Possible role of cyclooxygenase-2
88. Interleukin 6 induces the expression of vascular endothelial growth factor
89. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
90. Thromboxane A(2) regulation of endothelial cell migration, angiogenesis and tumor metastasis
91. Inflammation, reproduction, cancer and all that.... The regulation and role of the inducible prostaglandin synthase
92. Prostaglandin synthase 2
93. Vascular protection: A novel nonangiogenic cardiovascular role for vascular endothelial growth factor
94. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src
95. Effects of angiogenic growth factors on endothelium-derived prostacyclin production by ovine uterine and placental arteries
96. Chemotactic, mitogenic, and angiogenic actions of UTP on vascular endothelial cells
97. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin
98. Angiogenin stimulates endothelial cell prostacyclin secretion by activation of phospholipase A2
99. Engagement of human PECAM-1 (CD31) on human endothelial cells increases intracellular calcium ion concentration and stimulates prostacyclin release
100. Gangliosides, copper ions and angiogenic capacity of adult tissues
101. Prostaglandins and gangliosides of tumor microenvironment: Their role in angiogenesis
102. Angiogenesis can be stimulated or repressed in vivo by a change in GM3: GD3 ganglioside ratio
103. Gangliosides promote the angiogenic response
104. PGE2 and angiogenesis
105. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: A potential mechanism for inflammatory angtogenesis
106. Expression and regulation of vascular endothelial growth factor in osteoblasts
107. Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts
108. Intense vascular sprouting from rat femoral vein induced by prostaglandins E1 and E2
109. The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis
110. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells
111. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice
112. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells
113. Topology of prostaglandin H synthase-1 in the endoplasmic reticulum membrane
114. The orientation of prostaglandin endoperoxide synthases-1 and -2 in the endoplasmic reticulum
115. Subcellular localization of prostaglandin endoperoxide synthase-2 in murine 3T3 cells
116. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2
117. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression
118. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2
119. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway
120. Akt takes center stage in angiogenesis signaling
121. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells
122. Insulin-mediated stimulation of protein kinase Akt: A potent survival signaling cascade for endothelial cells
123. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial
124. Celecoxib: A review of its use in osteoarthritis, rheumatoid arthritis and acute pain
125. Nonsteroidal anti-inflammatory drugs, COX-2 and colorectal cancer
126. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison
127. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
128. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group
129. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease
130. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin
131. Enhancement of tumor response to gammaradiation by an inhibitor of cyclooxygenase-2 enzyme
132. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor
133. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
134. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
135. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
136. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
137. Nonsteroidal anti-inflammatory drugs (NSAIDs) in the prevention of colorectal cancer
138. COX-2 and colon cancer: Potential targets for chemoprevention
139. The role of COX-2 in intestinal cancer
140. Inhibition of cyclooxygenase-2 expression. An approach to preventing head and neck cancer
141. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis
142. Induction of angiogenesis during the transition from hyperplasia to neoplasia
143. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth
144. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice